#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Rarely , such influenza vaccines can cause allergic reactions such as hives , rapid swelling of deeper skin layers and tissues , asthma or a severe multisystem allergic reaction due to hypersensitivity to certain vaccine components .
1-1	0-6	Rarely	_	_	_	_
1-2	7-8	,	_	_	_	_
1-3	9-13	such	substance[2]	new[2]	coref	2-1[15_2]
1-4	14-23	influenza	abstract|substance[2]	new|new[2]	coref	3-12
1-5	24-32	vaccines	substance[2]	new[2]	_	_
1-6	33-36	can	_	_	_	_
1-7	37-42	cause	_	_	_	_
1-8	43-51	allergic	event[3]	new[3]	_	_
1-9	52-61	reactions	event[3]	new[3]	_	_
1-10	62-66	such	event[3]	new[3]	_	_
1-11	67-69	as	event[3]	new[3]	_	_
1-12	70-75	hives	event[3]|abstract	new[3]|new	_	_
1-13	76-77	,	event[3]	new[3]	_	_
1-14	78-83	rapid	event[3]|event[5]	new[3]|new[5]	_	_
1-15	84-92	swelling	event[3]|event[5]	new[3]|new[5]	_	_
1-16	93-95	of	event[3]|event[5]	new[3]|new[5]	_	_
1-17	96-102	deeper	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-18	103-107	skin	event[3]|event[5]|object|abstract[7]	new[3]|new[5]|new|new[7]	_	_
1-19	108-114	layers	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-20	115-118	and	event[3]|event[5]	new[3]|new[5]	_	_
1-21	119-126	tissues	event[3]|event[5]|object	new[3]|new[5]|new	_	_
1-22	127-128	,	event[3]	new[3]	_	_
1-23	129-135	asthma	event[3]|abstract	new[3]|new	_	_
1-24	136-138	or	event[3]	new[3]	_	_
1-25	139-140	a	event[3]|event[11]	new[3]|new[11]	_	_
1-26	141-147	severe	event[3]|event[11]	new[3]|new[11]	_	_
1-27	148-159	multisystem	event[3]|abstract|event[11]	new[3]|new|new[11]	_	_
1-28	160-168	allergic	event[3]|event[11]	new[3]|new[11]	_	_
1-29	169-177	reaction	event[3]|event[11]	new[3]|new[11]	_	_
1-30	178-181	due	event[3]|event[11]	new[3]|new[11]	_	_
1-31	182-184	to	event[3]|event[11]	new[3]|new[11]	_	_
1-32	185-201	hypersensitivity	event[3]|event[11]|abstract[12]	new[3]|new[11]|new[12]	_	_
1-33	202-204	to	event[3]|event[11]|abstract[12]	new[3]|new[11]|new[12]	_	_
1-34	205-212	certain	event[3]|event[11]|abstract[12]|substance[14]	new[3]|new[11]|new[12]|new[14]	_	_
1-35	213-220	vaccine	event[3]|event[11]|abstract[12]|substance|substance[14]	new[3]|new[11]|new[12]|new|new[14]	coref	5-18
1-36	221-231	components	event[3]|event[11]|abstract[12]|substance[14]	new[3]|new[11]|new[12]|new[14]	_	_
1-37	232-233	.	_	_	_	_

#Text=Live vaccines are given via a nasal spray , and can commonly cause runny nose , nasal congestion , cough , and can less frequently cause sore throat , low grade fever , irritability and head- and muscle- aches .
2-1	234-238	Live	substance[15]	giv[15]	coref	3-11[30_15]
2-2	239-247	vaccines	substance[15]	giv[15]	_	_
2-3	248-251	are	_	_	_	_
2-4	252-257	given	_	_	_	_
2-5	258-261	via	_	_	_	_
2-6	262-263	a	substance[16]	new[16]	_	_
2-7	264-269	nasal	substance[16]	new[16]	_	_
2-8	270-275	spray	substance[16]	new[16]	_	_
2-9	276-277	,	_	_	_	_
2-10	278-281	and	_	_	_	_
2-11	282-285	can	_	_	_	_
2-12	286-294	commonly	_	_	_	_
2-13	295-300	cause	_	_	_	_
2-14	301-306	runny	object[17]	new[17]	_	_
2-15	307-311	nose	object[17]	new[17]	_	_
2-16	312-313	,	_	_	_	_
2-17	314-319	nasal	abstract[18]	new[18]	_	_
2-18	320-330	congestion	abstract[18]	new[18]	_	_
2-19	331-332	,	_	_	_	_
2-20	333-338	cough	abstract	new	_	_
2-21	339-340	,	_	_	_	_
2-22	341-344	and	_	_	_	_
2-23	345-348	can	_	_	_	_
2-24	349-353	less	_	_	_	_
2-25	354-364	frequently	_	_	_	_
2-26	365-370	cause	_	_	_	_
2-27	371-375	sore	object[20]	new[20]	_	_
2-28	376-382	throat	object[20]	new[20]	_	_
2-29	383-384	,	_	_	_	_
2-30	385-388	low	abstract[21]|abstract[22]	new[21]|new[22]	ana	4-9[0_22]
2-31	389-394	grade	abstract[21]|abstract[22]	new[21]|new[22]	_	_
2-32	395-400	fever	abstract[22]	new[22]	_	_
2-33	401-402	,	_	_	_	_
2-34	403-415	irritability	event	new	_	_
2-35	416-419	and	_	_	_	_
2-36	420-425	head-	object|event[26]	new|new[26]	_	_
2-37	426-429	and	event[26]	new[26]	_	_
2-38	430-437	muscle-	object|event[26]	new|new[26]	_	_
2-39	438-443	aches	event[26]	new[26]	_	_
2-40	444-445	.	_	_	_	_

#Text=Wheezing and vomiting episodes have been described in children receiving live influenza vaccines .
3-1	446-454	Wheezing	event[27]	new[27]	_	_
3-2	455-458	and	event[27]	new[27]	_	_
3-3	459-467	vomiting	event[27]	new[27]	_	_
3-4	468-476	episodes	event[27]	new[27]	_	_
3-5	477-481	have	_	_	_	_
3-6	482-486	been	_	_	_	_
3-7	487-496	described	_	_	_	_
3-8	497-499	in	_	_	_	_
3-9	500-508	children	person[28]	new[28]	coref	20-26[176_28]
3-10	509-518	receiving	person[28]	new[28]	_	_
3-11	519-523	live	person[28]|substance[30]	new[28]|giv[30]	coref	4-13[0_30]
3-12	524-533	influenza	person[28]|abstract|substance[30]	new[28]|giv|giv[30]	coref	14-17
3-13	534-542	vaccines	person[28]|substance[30]	new[28]|giv[30]	_	_
3-14	543-544	.	_	_	_	_

#Text=What action has the WHO taken , if any , to insure vaccines are available ?
4-1	545-549	What	event[31]	new[31]	_	_
4-2	550-556	action	event[31]	new[31]	_	_
4-3	557-560	has	_	_	_	_
4-4	561-564	the	organization[32]	new[32]	coref	6-3[0_32]
4-5	565-568	WHO	organization[32]	new[32]	_	_
4-6	569-574	taken	_	_	_	_
4-7	575-576	,	_	_	_	_
4-8	577-579	if	_	_	_	_
4-9	580-583	any	abstract	giv	_	_
4-10	584-585	,	_	_	_	_
4-11	586-588	to	_	_	_	_
4-12	589-595	insure	_	_	_	_
4-13	596-604	vaccines	substance	giv	coref	6-27[55_0]
4-14	605-608	are	_	_	_	_
4-15	609-618	available	_	_	_	_
4-16	619-620	?	_	_	_	_

#Text=During the first stages of the pandemic in 2009 , the Director-General highlighted the need to make vaccine and medicines available to countries who would be unable to access them on their own .
5-1	621-627	During	_	_	_	_
5-2	628-631	the	time[35]	new[35]	_	_
5-3	632-637	first	time[35]	new[35]	_	_
5-4	638-644	stages	time[35]	new[35]	_	_
5-5	645-647	of	time[35]	new[35]	_	_
5-6	648-651	the	time[35]|event[36]	new[35]|new[36]	coref	6-4[0_36]
5-7	652-660	pandemic	time[35]|event[36]	new[35]|new[36]	_	_
5-8	661-663	in	time[35]	new[35]	_	_
5-9	664-668	2009	time[35]|time	new[35]|new	coref	25-3
5-10	669-670	,	_	_	_	_
5-11	671-674	the	person[38]	new[38]	_	_
5-12	675-691	Director-General	person[38]	new[38]	_	_
5-13	692-703	highlighted	_	_	_	_
5-14	704-707	the	abstract[39]	new[39]	_	_
5-15	708-712	need	abstract[39]	new[39]	_	_
5-16	713-715	to	abstract[39]	new[39]	_	_
5-17	716-720	make	abstract[39]	new[39]	_	_
5-18	721-728	vaccine	abstract[39]|substance	new[39]|giv	coref	6-4[47_0]
5-19	729-732	and	abstract[39]	new[39]	_	_
5-20	733-742	medicines	abstract[39]|substance	new[39]|new	_	_
5-21	743-752	available	abstract[39]	new[39]	_	_
5-22	753-755	to	_	_	_	_
5-23	756-765	countries	place[42]	new[42]	ana	5-30[0_42]
5-24	766-769	who	place[42]	new[42]	_	_
5-25	770-775	would	place[42]	new[42]	_	_
5-26	776-778	be	place[42]	new[42]	_	_
5-27	779-785	unable	place[42]	new[42]	_	_
5-28	786-788	to	place[42]	new[42]	_	_
5-29	789-795	access	place[42]	new[42]	_	_
5-30	796-800	them	place[42]|place	new[42]|giv	ana	5-32
5-31	801-803	on	_	_	_	_
5-32	804-809	their	place	giv	coref	6-12[50_0]
5-33	810-813	own	_	_	_	_
5-34	814-815	.	_	_	_	_

#Text=As the WHO pandemic vaccine donation programme was first established , all countries were surveyed by WHO , and 95 identified as having no access to pandemic vaccines , and therefore eligible for donations .
6-1	816-818	As	_	_	_	_
6-2	819-822	the	abstract[49]	new[49]	_	_
6-3	823-826	WHO	organization|abstract[49]	giv|new[49]	coref	6-17
6-4	827-835	pandemic	event|substance[47]|abstract[49]	giv|giv[47]|new[49]	coref|coref	6-27|7-6[58_47]
6-5	836-843	vaccine	substance[47]|abstract[49]	giv[47]|new[49]	_	_
6-6	844-852	donation	abstract|abstract[49]	new|new[49]	_	_
6-7	853-862	programme	abstract[49]	new[49]	_	_
6-8	863-866	was	_	_	_	_
6-9	867-872	first	_	_	_	_
6-10	873-884	established	_	_	_	_
6-11	885-886	,	_	_	_	_
6-12	887-890	all	place[50]	giv[50]	coref	7-29[65_50]
6-13	891-900	countries	place[50]	giv[50]	_	_
6-14	901-905	were	_	_	_	_
6-15	906-914	surveyed	_	_	_	_
6-16	915-917	by	_	_	_	_
6-17	918-921	WHO	organization	giv	coref	12-4[122_0]
6-18	922-923	,	_	_	_	_
6-19	924-927	and	_	_	_	_
6-20	928-930	95	person	new	_	_
6-21	931-941	identified	_	_	_	_
6-22	942-944	as	_	_	_	_
6-23	945-951	having	_	_	_	_
6-24	952-954	no	abstract[53]	new[53]	_	_
6-25	955-961	access	abstract[53]	new[53]	_	_
6-26	962-964	to	abstract[53]	new[53]	_	_
6-27	965-973	pandemic	abstract[53]|event|substance[55]	new[53]|giv|giv[55]	coref|coref	7-20[62_55]|8-12[79_0]
6-28	974-982	vaccines	abstract[53]|substance[55]	new[53]|giv[55]	_	_
6-29	983-984	,	_	_	_	_
6-30	985-988	and	_	_	_	_
6-31	989-998	therefore	_	_	_	_
6-32	999-1007	eligible	_	_	_	_
6-33	1008-1011	for	_	_	_	_
6-34	1012-1021	donations	event	new	_	_
6-35	1022-1023	.	_	_	_	_

#Text=Based on the pledges of donated vaccine , a plan was prepared for a two phase approach to supply sufficient vaccines for 10 % of the population in these countries ; an initial supply to cover health workers and other essential workers , equivalent to 2 % of the population , and a second supply of 8 % for other priority groups .
7-1	1024-1029	Based	_	_	_	_
7-2	1030-1032	on	_	_	_	_
7-3	1033-1036	the	abstract[57]	new[57]	_	_
7-4	1037-1044	pledges	abstract[57]	new[57]	_	_
7-5	1045-1047	of	abstract[57]	new[57]	_	_
7-6	1048-1055	donated	abstract[57]|substance[58]	new[57]|giv[58]	coref	9-8[85_58]
7-7	1056-1063	vaccine	abstract[57]|substance[58]	new[57]|giv[58]	_	_
7-8	1064-1065	,	_	_	_	_
7-9	1066-1067	a	abstract[59]	new[59]	_	_
7-10	1068-1072	plan	abstract[59]	new[59]	_	_
7-11	1073-1076	was	_	_	_	_
7-12	1077-1085	prepared	_	_	_	_
7-13	1086-1089	for	_	_	_	_
7-14	1090-1091	a	abstract[61]	new[61]	appos	7-32[66_61]
7-15	1092-1095	two	abstract[60]|abstract[61]	new[60]|new[61]	_	_
7-16	1096-1101	phase	abstract[60]|abstract[61]	new[60]|new[61]	_	_
7-17	1102-1110	approach	abstract[61]	new[61]	_	_
7-18	1111-1113	to	abstract[61]	new[61]	_	_
7-19	1114-1120	supply	abstract[61]	new[61]	_	_
7-20	1121-1131	sufficient	abstract[61]|substance[62]	new[61]|giv[62]	coref	8-19[0_62]
7-21	1132-1140	vaccines	abstract[61]|substance[62]	new[61]|giv[62]	_	_
7-22	1141-1144	for	abstract[61]|substance[62]	new[61]|giv[62]	_	_
7-23	1145-1147	10	abstract[61]|substance[62]|person[63]	new[61]|giv[62]|new[63]	_	_
7-24	1148-1149	%	abstract[61]|substance[62]|person[63]	new[61]|giv[62]|new[63]	_	_
7-25	1150-1152	of	abstract[61]|substance[62]|person[63]	new[61]|giv[62]|new[63]	_	_
7-26	1153-1156	the	abstract[61]|substance[62]|person[63]|person[64]	new[61]|giv[62]|new[63]|new[64]	coref	7-49[71_64]
7-27	1157-1167	population	abstract[61]|substance[62]|person[63]|person[64]	new[61]|giv[62]|new[63]|new[64]	_	_
7-28	1168-1170	in	abstract[61]|substance[62]|person[63]|person[64]	new[61]|giv[62]|new[63]|new[64]	_	_
7-29	1171-1176	these	abstract[61]|substance[62]|person[63]|person[64]|place[65]	new[61]|giv[62]|new[63]|new[64]|giv[65]	coref	9-4[83_65]
7-30	1177-1186	countries	abstract[61]|substance[62]|person[63]|person[64]|place[65]	new[61]|giv[62]|new[63]|new[64]|giv[65]	_	_
7-31	1187-1188	;	_	_	_	_
7-32	1189-1191	an	abstract[66]	giv[66]	coref	7-53[72_66]
7-33	1192-1199	initial	abstract[66]	giv[66]	_	_
7-34	1200-1206	supply	abstract[66]	giv[66]	_	_
7-35	1207-1209	to	abstract[66]	giv[66]	_	_
7-36	1210-1215	cover	abstract[66]	giv[66]	_	_
7-37	1216-1222	health	abstract[66]|abstract|person[68]	giv[66]|new|new[68]	coref	24-18[200_0]
7-38	1223-1230	workers	abstract[66]|person[68]	giv[66]|new[68]	_	_
7-39	1231-1234	and	abstract[66]	giv[66]	_	_
7-40	1235-1240	other	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-41	1241-1250	essential	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-42	1251-1258	workers	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-43	1259-1260	,	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-44	1261-1271	equivalent	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-45	1272-1274	to	abstract[66]|person[69]	giv[66]|new[69]	_	_
7-46	1275-1276	2	abstract[66]|person[69]|abstract[70]	giv[66]|new[69]|new[70]	_	_
7-47	1277-1278	%	abstract[66]|person[69]|abstract[70]	giv[66]|new[69]|new[70]	_	_
7-48	1279-1281	of	abstract[66]|person[69]|abstract[70]	giv[66]|new[69]|new[70]	_	_
7-49	1282-1285	the	abstract[66]|person[69]|abstract[70]|person[71]	giv[66]|new[69]|new[70]|giv[71]	_	_
7-50	1286-1296	population	abstract[66]|person[69]|abstract[70]|person[71]	giv[66]|new[69]|new[70]|giv[71]	_	_
7-51	1297-1298	,	_	_	_	_
7-52	1299-1302	and	_	_	_	_
7-53	1303-1304	a	abstract[72]	giv[72]	coref	8-4[0_72]
7-54	1305-1311	second	abstract[72]	giv[72]	_	_
7-55	1312-1318	supply	abstract[72]	giv[72]	_	_
7-56	1319-1321	of	abstract[72]	giv[72]	_	_
7-57	1322-1323	8	abstract[72]|abstract[73]	giv[72]|new[73]	_	_
7-58	1324-1325	%	abstract[72]|abstract[73]	giv[72]|new[73]	_	_
7-59	1326-1329	for	abstract[72]	giv[72]	_	_
7-60	1330-1335	other	abstract[72]|person[74]	giv[72]|new[74]	coref	20-3[170_74]
7-61	1336-1344	priority	abstract[72]|person[74]	giv[72]|new[74]	_	_
7-62	1345-1351	groups	abstract[72]|person[74]	giv[72]|new[74]	_	_
7-63	1352-1353	.	_	_	_	_

#Text=The sequencing of supply was based on assessments of vulnerability to the pandemic , and readiness to utilize vaccines .
8-1	1354-1357	The	abstract[75]	new[75]	_	_
8-2	1358-1368	sequencing	abstract[75]	new[75]	_	_
8-3	1369-1371	of	abstract[75]	new[75]	_	_
8-4	1372-1378	supply	abstract[75]|abstract	new[75]|giv	_	_
8-5	1379-1382	was	_	_	_	_
8-6	1383-1388	based	_	_	_	_
8-7	1389-1391	on	_	_	_	_
8-8	1392-1403	assessments	abstract[77]	new[77]	_	_
8-9	1404-1406	of	abstract[77]	new[77]	_	_
8-10	1407-1420	vulnerability	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-11	1421-1423	to	abstract[77]|abstract[78]	new[77]|new[78]	_	_
8-12	1424-1427	the	abstract[77]|abstract[78]|event[79]	new[77]|new[78]|giv[79]	coref	16-31[0_79]
8-13	1428-1436	pandemic	abstract[77]|abstract[78]|event[79]	new[77]|new[78]|giv[79]	_	_
8-14	1437-1438	,	abstract[77]	new[77]	_	_
8-15	1439-1442	and	abstract[77]	new[77]	_	_
8-16	1443-1452	readiness	abstract[77]|abstract[80]	new[77]|new[80]	_	_
8-17	1453-1455	to	abstract[77]|abstract[80]	new[77]|new[80]	_	_
8-18	1456-1463	utilize	abstract[77]|abstract[80]	new[77]|new[80]	_	_
8-19	1464-1472	vaccines	abstract[77]|abstract[80]|substance	new[77]|new[80]|giv	coref	15-21[141_0]
8-20	1473-1474	.	_	_	_	_

#Text=To date , 25 countries have received donated H1N1 vaccine totaling more than 10 million doses , along with ancillary supplies .
9-1	1475-1477	To	_	_	_	_
9-2	1478-1482	date	time	new	_	_
9-3	1483-1484	,	_	_	_	_
9-4	1485-1487	25	place[83]	giv[83]	coref	10-1[88_83]
9-5	1488-1497	countries	place[83]	giv[83]	_	_
9-6	1498-1502	have	_	_	_	_
9-7	1503-1511	received	_	_	_	_
9-8	1512-1519	donated	substance[85]	giv[85]	coref	10-10[0_85]
9-9	1520-1524	H1N1	abstract|substance[85]	new|giv[85]	coref	12-8
9-10	1525-1532	vaccine	substance[85]	giv[85]	_	_
9-11	1533-1541	totaling	substance[85]	giv[85]	_	_
9-12	1542-1546	more	substance[85]|abstract[86]	giv[85]|new[86]	_	_
9-13	1547-1551	than	substance[85]|abstract[86]	giv[85]|new[86]	_	_
9-14	1552-1554	10	substance[85]|abstract[86]	giv[85]|new[86]	_	_
9-15	1555-1562	million	substance[85]|abstract[86]	giv[85]|new[86]	_	_
9-16	1563-1568	doses	substance[85]|abstract[86]	giv[85]|new[86]	_	_
9-17	1569-1570	,	_	_	_	_
9-18	1571-1576	along	object[87]	new[87]	_	_
9-19	1577-1581	with	object[87]	new[87]	_	_
9-20	1582-1591	ancillary	object[87]	new[87]	_	_
9-21	1592-1600	supplies	object[87]	new[87]	_	_
9-22	1601-1602	.	_	_	_	_

#Text=Another 15 to 20 countries will be receiving their vaccine shipments in the upcoming few weeks .
10-1	1603-1610	Another	place[88]	giv[88]	ana	10-9[0_88]
10-2	1611-1613	15	place[88]	giv[88]	_	_
10-3	1614-1616	to	place[88]	giv[88]	_	_
10-4	1617-1619	20	place[88]	giv[88]	_	_
10-5	1620-1629	countries	place[88]	giv[88]	_	_
10-6	1630-1634	will	_	_	_	_
10-7	1635-1637	be	_	_	_	_
10-8	1638-1647	receiving	_	_	_	_
10-9	1648-1653	their	place|object[91]	giv|new[91]	coref|coref	11-1[93_0]|11-7[0_91]
10-10	1654-1661	vaccine	substance|object[91]	giv|new[91]	coref	14-13
10-11	1662-1671	shipments	object[91]	new[91]	_	_
10-12	1672-1674	in	_	_	_	_
10-13	1675-1678	the	time[92]	new[92]	_	_
10-14	1679-1687	upcoming	time[92]	new[92]	_	_
10-15	1688-1691	few	time[92]	new[92]	_	_
10-16	1692-1697	weeks	time[92]	new[92]	_	_
10-17	1698-1699	.	_	_	_	_

#Text=The 25 countries who have received shipments are : Azerbaijan , Afghanistan , Cambodia , Fiji , Kiribati , Kosovo , Laos PDR , Maldives , Mongolia , Nauru , Nicaragua , Papua New Guinea , Solomon Islands , Togo , Tonga , Vanuatu , Cuba , Honduras , El Salvador , Kenya , Samoa , Tokelau , Cook Islands , Pakistan , [ and ] Philippines
11-1	1700-1703	The	place[93]	giv[93]	coref	11-10[0_93]
11-2	1704-1706	25	place[93]	giv[93]	_	_
11-3	1707-1716	countries	place[93]	giv[93]	_	_
11-4	1717-1720	who	place[93]	giv[93]	_	_
11-5	1721-1725	have	place[93]	giv[93]	_	_
11-6	1726-1734	received	place[93]	giv[93]	_	_
11-7	1735-1744	shipments	place[93]|object	giv[93]|giv	_	_
11-8	1745-1748	are	_	_	_	_
11-9	1749-1750	:	_	_	_	_
11-10	1751-1761	Azerbaijan	place	giv	coref	25-5[208_0]
11-11	1762-1763	,	_	_	_	_
11-12	1764-1775	Afghanistan	place	new	_	_
11-13	1776-1777	,	_	_	_	_
11-14	1778-1786	Cambodia	place	new	_	_
11-15	1787-1788	,	_	_	_	_
11-16	1789-1793	Fiji	place	new	_	_
11-17	1794-1795	,	_	_	_	_
11-18	1796-1804	Kiribati	place	new	_	_
11-19	1805-1806	,	_	_	_	_
11-20	1807-1813	Kosovo	place	new	_	_
11-21	1814-1815	,	_	_	_	_
11-22	1816-1820	Laos	place|organization[102]	new|new[102]	_	_
11-23	1821-1824	PDR	organization[102]	new[102]	_	_
11-24	1825-1826	,	_	_	_	_
11-25	1827-1835	Maldives	place	new	_	_
11-26	1836-1837	,	_	_	_	_
11-27	1838-1846	Mongolia	place	new	_	_
11-28	1847-1848	,	_	_	_	_
11-29	1849-1854	Nauru	place	new	_	_
11-30	1855-1856	,	_	_	_	_
11-31	1857-1866	Nicaragua	place	new	_	_
11-32	1867-1868	,	_	_	_	_
11-33	1869-1874	Papua	_	_	_	_
11-34	1875-1878	New	place[107]	new[107]	_	_
11-35	1879-1885	Guinea	place[107]	new[107]	_	_
11-36	1886-1887	,	_	_	_	_
11-37	1888-1895	Solomon	place[108]	new[108]	coref	11-59[118_108]
11-38	1896-1903	Islands	place[108]	new[108]	_	_
11-39	1904-1905	,	_	_	_	_
11-40	1906-1910	Togo	place	new	_	_
11-41	1911-1912	,	_	_	_	_
11-42	1913-1918	Tonga	place	new	_	_
11-43	1919-1920	,	_	_	_	_
11-44	1921-1928	Vanuatu	place	new	_	_
11-45	1929-1930	,	_	_	_	_
11-46	1931-1935	Cuba	place	new	_	_
11-47	1936-1937	,	_	_	_	_
11-48	1938-1946	Honduras	place	new	_	_
11-49	1947-1948	,	_	_	_	_
11-50	1949-1951	El	place[114]	new[114]	_	_
11-51	1952-1960	Salvador	place[114]	new[114]	_	_
11-52	1961-1962	,	_	_	_	_
11-53	1963-1968	Kenya	place	new	_	_
11-54	1969-1970	,	_	_	_	_
11-55	1971-1976	Samoa	place	new	_	_
11-56	1977-1978	,	_	_	_	_
11-57	1979-1986	Tokelau	place	new	_	_
11-58	1987-1988	,	_	_	_	_
11-59	1989-1993	Cook	place[118]	giv[118]	_	_
11-60	1994-2001	Islands	place[118]	giv[118]	_	_
11-61	2002-2003	,	_	_	_	_
11-62	2004-2012	Pakistan	place	new	_	_
11-63	2013-2014	,	_	_	_	_
11-64	2015-2016	[	_	_	_	_
11-65	2017-2020	and	_	_	_	_
11-66	2021-2022	]	_	_	_	_
11-67	2023-2034	Philippines	place	new	_	_

#Text=Last November , the WHO stated the H1N1 virus is world 's most dominant virus .
12-1	2035-2039	Last	time[121]	new[121]	_	_
12-2	2040-2048	November	time[121]	new[121]	_	_
12-3	2049-2050	,	_	_	_	_
12-4	2051-2054	the	organization[122]	giv[122]	ana	13-2[0_122]
12-5	2055-2058	WHO	organization[122]	giv[122]	_	_
12-6	2059-2065	stated	_	_	_	_
12-7	2066-2069	the	abstract[124]	new[124]	coref	12-11[126_124]
12-8	2070-2074	H1N1	abstract|abstract[124]	giv|new[124]	coref	16-32
12-9	2075-2080	virus	abstract[124]	new[124]	_	_
12-10	2081-2083	is	_	_	_	_
12-11	2084-2089	world	place[125]|abstract[126]	new[125]|giv[126]	coref	16-27[148_125]
12-12	2090-2092	's	place[125]|abstract[126]	new[125]|giv[126]	_	_
12-13	2093-2097	most	abstract[126]	giv[126]	_	_
12-14	2098-2106	dominant	abstract[126]	giv[126]	_	_
12-15	2107-2112	virus	abstract[126]	giv[126]	_	_
12-16	2113-2114	.	_	_	_	_

#Text=Is this still true ?
13-1	2115-2117	Is	_	_	_	_
13-2	2118-2122	this	organization	giv	coref	14-5
13-3	2123-2128	still	_	_	_	_
13-4	2129-2133	true	_	_	_	_
13-5	2134-2135	?	_	_	_	_

#Text=On February 18th , WHO concluded a four-day meeting to look at vaccine strains for seasonal influenza vaccine for the 2010 and 2011 season .
14-1	2136-2138	On	_	_	_	_
14-2	2139-2147	February	_	_	_	_
14-3	2148-2152	18th	_	_	_	_
14-4	2153-2154	,	_	_	_	_
14-5	2155-2158	WHO	organization	giv	coref	15-9
14-6	2159-2168	concluded	_	_	_	_
14-7	2169-2170	a	event[129]	new[129]	ana	15-1[0_129]
14-8	2171-2179	four-day	event[129]	new[129]	_	_
14-9	2180-2187	meeting	event[129]	new[129]	_	_
14-10	2188-2190	to	event[129]	new[129]	_	_
14-11	2191-2195	look	event[129]	new[129]	_	_
14-12	2196-2198	at	event[129]	new[129]	_	_
14-13	2199-2206	vaccine	event[129]|substance|abstract[131]	new[129]|giv|new[131]	coref|coref	14-16[133_0]|15-15[139_131]
14-14	2207-2214	strains	event[129]|abstract[131]	new[129]|new[131]	_	_
14-15	2215-2218	for	event[129]|abstract[131]	new[129]|new[131]	_	_
14-16	2219-2227	seasonal	event[129]|abstract[131]|substance[133]	new[129]|new[131]|giv[133]	coref	15-15[0_133]
14-17	2228-2237	influenza	event[129]|abstract[131]|abstract|substance[133]	new[129]|new[131]|giv|giv[133]	coref	15-26[140_0]
14-18	2238-2245	vaccine	event[129]|abstract[131]|substance[133]	new[129]|new[131]|giv[133]	_	_
14-19	2246-2249	for	event[129]|abstract[131]	new[129]|new[131]	_	_
14-20	2250-2253	the	event[129]|abstract[131]|time[134]	new[129]|new[131]|new[134]	coref	17-25[160_134]
14-21	2254-2258	2010	event[129]|abstract[131]|time[134]	new[129]|new[131]|new[134]	_	_
14-22	2259-2262	and	event[129]|abstract[131]|time[134]	new[129]|new[131]|new[134]	_	_
14-23	2263-2267	2011	event[129]|abstract[131]|time[134]	new[129]|new[131]|new[134]	_	_
14-24	2268-2274	season	event[129]|abstract[131]|time[134]	new[129]|new[131]|new[134]	_	_
14-25	2275-2276	.	_	_	_	_

#Text=This is part of the routine work that WHO does twice yearly to determine vaccine strains to be included in upcoming northern and southern hemisphere seasonal influenza vaccines .
15-1	2277-2281	This	event	giv	_	_
15-2	2282-2284	is	_	_	_	_
15-3	2285-2289	part	_	_	_	_
15-4	2290-2292	of	_	_	_	_
15-5	2293-2296	the	abstract[136]	new[136]	ana	16-13[0_136]
15-6	2297-2304	routine	abstract[136]	new[136]	_	_
15-7	2305-2309	work	abstract[136]	new[136]	_	_
15-8	2310-2314	that	abstract[136]	new[136]	_	_
15-9	2315-2318	WHO	abstract[136]|organization	new[136]|giv	coref	18-5[162_0]
15-10	2319-2323	does	abstract[136]	new[136]	_	_
15-11	2324-2329	twice	abstract[136]	new[136]	_	_
15-12	2330-2336	yearly	abstract[136]	new[136]	_	_
15-13	2337-2339	to	_	_	_	_
15-14	2340-2349	determine	_	_	_	_
15-15	2350-2357	vaccine	substance|abstract[139]	giv|giv[139]	coref	24-12[199_0]
15-16	2358-2365	strains	abstract[139]	giv[139]	_	_
15-17	2366-2368	to	abstract[139]	giv[139]	_	_
15-18	2369-2371	be	abstract[139]	giv[139]	_	_
15-19	2372-2380	included	abstract[139]	giv[139]	_	_
15-20	2381-2383	in	abstract[139]	giv[139]	_	_
15-21	2384-2392	upcoming	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-22	2393-2401	northern	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-23	2402-2405	and	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-24	2406-2414	southern	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-25	2415-2425	hemisphere	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-26	2426-2434	seasonal	abstract[139]|abstract[140]|substance[141]	giv[139]|giv[140]|giv[141]	coref	16-21[0_140]
15-27	2435-2444	influenza	abstract[139]|abstract[140]|substance[141]	giv[139]|giv[140]|giv[141]	_	_
15-28	2445-2453	vaccines	abstract[139]|substance[141]	giv[139]|giv[141]	_	_
15-29	2454-2455	.	_	_	_	_

#Text=During the scientific discussions which ended on the 18th of February , it was confirmed that the overwhelming number of influenza viruses that were isolated around the world were the pandemic H1N1 virus .
16-1	2456-2462	During	_	_	_	_
16-2	2463-2466	the	event[142]	new[142]	_	_
16-3	2467-2477	scientific	event[142]	new[142]	_	_
16-4	2478-2489	discussions	event[142]	new[142]	_	_
16-5	2490-2495	which	event[142]	new[142]	_	_
16-6	2496-2501	ended	event[142]	new[142]	_	_
16-7	2502-2504	on	event[142]	new[142]	_	_
16-8	2505-2508	the	event[142]	new[142]	_	_
16-9	2509-2513	18th	event[142]	new[142]	_	_
16-10	2514-2516	of	event[142]	new[142]	_	_
16-11	2517-2525	February	event[142]|time	new[142]|new	_	_
16-12	2526-2527	,	_	_	_	_
16-13	2528-2530	it	abstract	giv	_	_
16-14	2531-2534	was	_	_	_	_
16-15	2535-2544	confirmed	_	_	_	_
16-16	2545-2549	that	_	_	_	_
16-17	2550-2553	the	abstract[145]	new[145]	coref	16-30[151_145]
16-18	2554-2566	overwhelming	abstract[145]	new[145]	_	_
16-19	2567-2573	number	abstract[145]	new[145]	_	_
16-20	2574-2576	of	abstract[145]	new[145]	_	_
16-21	2577-2586	influenza	abstract[145]|abstract|abstract[147]	new[145]|giv|new[147]	coref|coref	17-18[156_147]|21-25[182_0]
16-22	2587-2594	viruses	abstract[145]|abstract[147]	new[145]|new[147]	_	_
16-23	2595-2599	that	abstract[145]|abstract[147]	new[145]|new[147]	_	_
16-24	2600-2604	were	abstract[145]|abstract[147]	new[145]|new[147]	_	_
16-25	2605-2613	isolated	abstract[145]|abstract[147]	new[145]|new[147]	_	_
16-26	2614-2620	around	abstract[145]|abstract[147]	new[145]|new[147]	_	_
16-27	2621-2624	the	abstract[145]|abstract[147]|place[148]	new[145]|new[147]|giv[148]	_	_
16-28	2625-2630	world	abstract[145]|abstract[147]|place[148]	new[145]|new[147]|giv[148]	_	_
16-29	2631-2635	were	_	_	_	_
16-30	2636-2639	the	abstract[151]	giv[151]	coref	17-10[154_151]
16-31	2640-2648	pandemic	event|abstract[151]	giv|giv[151]	coref	19-5[166_0]
16-32	2649-2653	H1N1	abstract|abstract[151]	giv|giv[151]	coref	18-18[164_0]
16-33	2654-2659	virus	abstract[151]	giv[151]	_	_
16-34	2660-2661	.	_	_	_	_

#Text=The experts believe that based on this information that this virus will continue to be one of the dominant viruses in wide circulation in the coming fall and winter season .
17-1	2662-2665	The	person[152]	new[152]	_	_
17-2	2666-2673	experts	person[152]	new[152]	_	_
17-3	2674-2681	believe	_	_	_	_
17-4	2682-2686	that	_	_	_	_
17-5	2687-2692	based	_	_	_	_
17-6	2693-2695	on	_	_	_	_
17-7	2696-2700	this	abstract[153]	new[153]	_	_
17-8	2701-2712	information	abstract[153]	new[153]	_	_
17-9	2713-2717	that	_	_	_	_
17-10	2718-2722	this	abstract[154]	giv[154]	coref	17-16[155_154]
17-11	2723-2728	virus	abstract[154]	giv[154]	_	_
17-12	2729-2733	will	_	_	_	_
17-13	2734-2742	continue	_	_	_	_
17-14	2743-2745	to	_	_	_	_
17-15	2746-2748	be	_	_	_	_
17-16	2749-2752	one	abstract[155]	giv[155]	coref	23-7[191_155]
17-17	2753-2755	of	abstract[155]	giv[155]	_	_
17-18	2756-2759	the	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-19	2760-2768	dominant	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-20	2769-2776	viruses	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-21	2777-2779	in	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
17-22	2780-2784	wide	abstract[155]|abstract[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
17-23	2785-2796	circulation	abstract[155]|abstract[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
17-24	2797-2799	in	abstract[155]	giv[155]	_	_
17-25	2800-2803	the	abstract[155]|time[160]	giv[155]|giv[160]	_	_
17-26	2804-2810	coming	abstract[155]|time[160]	giv[155]|giv[160]	_	_
17-27	2811-2815	fall	abstract[155]|time|time[160]	giv[155]|new|giv[160]	_	_
17-28	2816-2819	and	abstract[155]|time[160]	giv[155]|giv[160]	_	_
17-29	2820-2826	winter	abstract[155]|abstract|time[160]	giv[155]|new|giv[160]	_	_
17-30	2827-2833	season	abstract[155]|time[160]	giv[155]|giv[160]	_	_
17-31	2834-2835	.	_	_	_	_

#Text=Is there anything that the WHO believes to be very important for the public to know about the H1N1 ?
18-1	2836-2838	Is	_	_	_	_
18-2	2839-2844	there	_	_	_	_
18-3	2845-2853	anything	object[161]	new[161]	_	_
18-4	2854-2858	that	object[161]	new[161]	_	_
18-5	2859-2862	the	object[161]|organization[162]	new[161]|giv[162]	_	_
18-6	2863-2866	WHO	object[161]|organization[162]	new[161]|giv[162]	_	_
18-7	2867-2875	believes	object[161]	new[161]	_	_
18-8	2876-2878	to	object[161]	new[161]	_	_
18-9	2879-2881	be	object[161]	new[161]	_	_
18-10	2882-2886	very	object[161]	new[161]	_	_
18-11	2887-2896	important	object[161]	new[161]	_	_
18-12	2897-2900	for	object[161]	new[161]	_	_
18-13	2901-2904	the	object[161]|person[163]	new[161]|new[163]	_	_
18-14	2905-2911	public	object[161]|person[163]	new[161]|new[163]	_	_
18-15	2912-2914	to	object[161]	new[161]	_	_
18-16	2915-2919	know	object[161]	new[161]	_	_
18-17	2920-2925	about	_	_	_	_
18-18	2926-2929	the	abstract[164]	giv[164]	coref	24-13[0_164]
18-19	2930-2934	H1N1	abstract[164]	giv[164]	_	_
18-20	2935-2936	?	_	_	_	_

#Text=The overall impact of the pandemic has been moderate and most people experienced mild symptoms or illness .
19-1	2937-2940	The	abstract[165]	new[165]	_	_
19-2	2941-2948	overall	abstract[165]	new[165]	_	_
19-3	2949-2955	impact	abstract[165]	new[165]	_	_
19-4	2956-2958	of	abstract[165]	new[165]	_	_
19-5	2959-2962	the	abstract[165]|event[166]	new[165]|giv[166]	coref	24-25[0_166]
19-6	2963-2971	pandemic	abstract[165]|event[166]	new[165]|giv[166]	_	_
19-7	2972-2975	has	_	_	_	_
19-8	2976-2980	been	_	_	_	_
19-9	2981-2989	moderate	_	_	_	_
19-10	2990-2993	and	_	_	_	_
19-11	2994-2998	most	person[167]	new[167]	coref	20-29[177_167]
19-12	2999-3005	people	person[167]	new[167]	_	_
19-13	3006-3017	experienced	_	_	_	_
19-14	3018-3022	mild	abstract[168]	new[168]	_	_
19-15	3023-3031	symptoms	abstract[168]	new[168]	_	_
19-16	3032-3034	or	_	_	_	_
19-17	3035-3042	illness	abstract	new	coref	20-16[173_0]
19-18	3043-3044	.	_	_	_	_

#Text=However , some groups are more vulnerable and have a higher risk of complications or severe illness , for example pregnant women , infants , young children and people with chronic diseases .
20-1	3045-3052	However	_	_	_	_
20-2	3053-3054	,	_	_	_	_
20-3	3055-3059	some	person[170]	giv[170]	_	_
20-4	3060-3066	groups	person[170]	giv[170]	_	_
20-5	3067-3070	are	_	_	_	_
20-6	3071-3075	more	_	_	_	_
20-7	3076-3086	vulnerable	_	_	_	_
20-8	3087-3090	and	_	_	_	_
20-9	3091-3095	have	_	_	_	_
20-10	3096-3097	a	abstract[171]	new[171]	_	_
20-11	3098-3104	higher	abstract[171]	new[171]	_	_
20-12	3105-3109	risk	abstract[171]	new[171]	_	_
20-13	3110-3112	of	abstract[171]	new[171]	_	_
20-14	3113-3126	complications	abstract[171]|abstract	new[171]|new	_	_
20-15	3127-3129	or	abstract[171]	new[171]	_	_
20-16	3130-3136	severe	abstract[171]|abstract[173]	new[171]|giv[173]	coref	24-32[0_173]
20-17	3137-3144	illness	abstract[171]|abstract[173]	new[171]|giv[173]	_	_
20-18	3145-3146	,	abstract[171]	new[171]	_	_
20-19	3147-3150	for	abstract[171]	new[171]	_	_
20-20	3151-3158	example	abstract[171]|person[174]	new[171]|new[174]	_	_
20-21	3159-3167	pregnant	abstract[171]|person[174]	new[171]|new[174]	_	_
20-22	3168-3173	women	abstract[171]|person[174]	new[171]|new[174]	_	_
20-23	3174-3175	,	abstract[171]	new[171]	_	_
20-24	3176-3183	infants	abstract[171]|animal	new[171]|new	_	_
20-25	3184-3185	,	abstract[171]	new[171]	_	_
20-26	3186-3191	young	abstract[171]|person[176]	new[171]|giv[176]	_	_
20-27	3192-3200	children	abstract[171]|person[176]	new[171]|giv[176]	_	_
20-28	3201-3204	and	abstract[171]	new[171]	_	_
20-29	3205-3211	people	abstract[171]|person[177]	new[171]|giv[177]	coref	23-13[192_177]
20-30	3212-3216	with	abstract[171]|person[177]	new[171]|giv[177]	_	_
20-31	3217-3224	chronic	abstract[171]|person[177]|abstract[178]	new[171]|giv[177]|new[178]	_	_
20-32	3225-3233	diseases	abstract[171]|person[177]|abstract[178]	new[171]|giv[177]|new[178]	_	_
20-33	3234-3235	.	_	_	_	_

#Text=Many of the severe cases have been due to viral pneumonia , which is harder to treat than the bacterial pneumonia normally associated with seasonal influenza .
21-1	3236-3240	Many	_	_	_	_
21-2	3241-3243	of	_	_	_	_
21-3	3244-3247	the	event[179]	new[179]	_	_
21-4	3248-3254	severe	event[179]	new[179]	_	_
21-5	3255-3260	cases	event[179]	new[179]	_	_
21-6	3261-3265	have	_	_	_	_
21-7	3266-3270	been	_	_	_	_
21-8	3271-3274	due	_	_	_	_
21-9	3275-3277	to	_	_	_	_
21-10	3278-3283	viral	abstract[180]	new[180]	coref	21-19[181_180]
21-11	3284-3293	pneumonia	abstract[180]	new[180]	_	_
21-12	3294-3295	,	abstract[180]	new[180]	_	_
21-13	3296-3301	which	abstract[180]	new[180]	_	_
21-14	3302-3304	is	abstract[180]	new[180]	_	_
21-15	3305-3311	harder	abstract[180]	new[180]	_	_
21-16	3312-3314	to	abstract[180]	new[180]	_	_
21-17	3315-3320	treat	abstract[180]	new[180]	_	_
21-18	3321-3325	than	_	_	_	_
21-19	3326-3329	the	abstract[181]	giv[181]	_	_
21-20	3330-3339	bacterial	abstract[181]	giv[181]	_	_
21-21	3340-3349	pneumonia	abstract[181]	giv[181]	_	_
21-22	3350-3358	normally	abstract[181]	giv[181]	_	_
21-23	3359-3369	associated	abstract[181]	giv[181]	_	_
21-24	3370-3374	with	abstract[181]	giv[181]	_	_
21-25	3375-3383	seasonal	abstract[181]|abstract[182]	giv[181]|giv[182]	coref	23-9[0_182]
21-26	3384-3393	influenza	abstract[181]|abstract[182]	giv[181]|giv[182]	_	_
21-27	3394-3395	.	_	_	_	_

#Text=Many of these patients have required intensive care , which has led to intensive care units being frequently overwhelmed at the peak of the outbreak .
22-1	3396-3400	Many	_	_	_	_
22-2	3401-3403	of	_	_	_	_
22-3	3404-3409	these	person[183]	new[183]	_	_
22-4	3410-3418	patients	person[183]	new[183]	_	_
22-5	3419-3423	have	_	_	_	_
22-6	3424-3432	required	_	_	_	_
22-7	3433-3442	intensive	abstract[184]	new[184]	coref	22-14[185_184]
22-8	3443-3447	care	abstract[184]	new[184]	_	_
22-9	3448-3449	,	abstract[184]	new[184]	_	_
22-10	3450-3455	which	abstract[184]	new[184]	_	_
22-11	3456-3459	has	abstract[184]	new[184]	_	_
22-12	3460-3463	led	abstract[184]	new[184]	_	_
22-13	3464-3466	to	_	_	_	_
22-14	3467-3476	intensive	abstract[185]|organization[186]	giv[185]|new[186]	_	_
22-15	3477-3481	care	abstract[185]|organization[186]	giv[185]|new[186]	_	_
22-16	3482-3487	units	organization[186]	new[186]	_	_
22-17	3488-3493	being	_	_	_	_
22-18	3494-3504	frequently	_	_	_	_
22-19	3505-3516	overwhelmed	_	_	_	_
22-20	3517-3519	at	_	_	_	_
22-21	3520-3523	the	time[187]	new[187]	_	_
22-22	3524-3528	peak	time[187]	new[187]	_	_
22-23	3529-3531	of	time[187]	new[187]	_	_
22-24	3532-3535	the	time[187]|event[188]	new[187]|new[188]	_	_
22-25	3536-3544	outbreak	time[187]|event[188]	new[187]|new[188]	_	_
22-26	3545-3546	.	_	_	_	_

#Text=Most of the deaths caused by the pandemic influenza disease occurred among younger people than is the case during seasonal influenza outbreaks , including among those who were previously healthy .
23-1	3547-3551	Most	event[189]	new[189]	_	_
23-2	3552-3554	of	event[189]	new[189]	_	_
23-3	3555-3558	the	event[189]	new[189]	_	_
23-4	3559-3565	deaths	event[189]	new[189]	_	_
23-5	3566-3572	caused	event[189]	new[189]	_	_
23-6	3573-3575	by	event[189]	new[189]	_	_
23-7	3576-3579	the	event[189]|abstract[191]	new[189]|giv[191]	coref	24-24[204_191]
23-8	3580-3588	pandemic	event[189]|abstract[191]	new[189]|giv[191]	_	_
23-9	3589-3598	influenza	event[189]|abstract|abstract[191]	new[189]|giv|giv[191]	coref	23-20[193_0]
23-10	3599-3606	disease	event[189]|abstract[191]	new[189]|giv[191]	_	_
23-11	3607-3615	occurred	_	_	_	_
23-12	3616-3621	among	_	_	_	_
23-13	3622-3629	younger	person[192]	giv[192]	coref	24-3[0_192]
23-14	3630-3636	people	person[192]	giv[192]	_	_
23-15	3637-3641	than	person[192]	giv[192]	_	_
23-16	3642-3644	is	person[192]	giv[192]	_	_
23-17	3645-3648	the	person[192]	giv[192]	_	_
23-18	3649-3653	case	person[192]	giv[192]	_	_
23-19	3654-3660	during	person[192]	giv[192]	_	_
23-20	3661-3669	seasonal	person[192]|abstract[193]|event[194]	giv[192]|giv[193]|new[194]	_	_
23-21	3670-3679	influenza	person[192]|abstract[193]|event[194]	giv[192]|giv[193]|new[194]	_	_
23-22	3680-3689	outbreaks	person[192]|event[194]	giv[192]|new[194]	_	_
23-23	3690-3691	,	_	_	_	_
23-24	3692-3701	including	_	_	_	_
23-25	3702-3707	among	_	_	_	_
23-26	3708-3713	those	_	_	_	_
23-27	3714-3717	who	_	_	_	_
23-28	3718-3722	were	_	_	_	_
23-29	3723-3733	previously	_	_	_	_
23-30	3734-3741	healthy	_	_	_	_
23-31	3742-3743	.	_	_	_	_

#Text=To protect people from infection and avoid related severe outcomes , the H1N1 vaccine is an important public health tool as long as the pandemic H1N1 virus is circulating and causing illness .
24-1	3744-3746	To	_	_	_	_
24-2	3747-3754	protect	_	_	_	_
24-3	3755-3761	people	person	giv	_	_
24-4	3762-3766	from	_	_	_	_
24-5	3767-3776	infection	event	new	_	_
24-6	3777-3780	and	_	_	_	_
24-7	3781-3786	avoid	_	_	_	_
24-8	3787-3794	related	event[197]	new[197]	_	_
24-9	3795-3801	severe	event[197]	new[197]	_	_
24-10	3802-3810	outcomes	event[197]	new[197]	_	_
24-11	3811-3812	,	_	_	_	_
24-12	3813-3816	the	substance[199]	giv[199]	coref	24-16[201_199]
24-13	3817-3821	H1N1	abstract|substance[199]	giv|giv[199]	coref	24-26
24-14	3822-3829	vaccine	substance[199]	giv[199]	_	_
24-15	3830-3832	is	_	_	_	_
24-16	3833-3835	an	substance[201]	giv[201]	coref	25-22[217_201]
24-17	3836-3845	important	substance[201]	giv[201]	_	_
24-18	3846-3852	public	abstract[200]|substance[201]	giv[200]|giv[201]	_	_
24-19	3853-3859	health	abstract[200]|substance[201]	giv[200]|giv[201]	_	_
24-20	3860-3864	tool	substance[201]	giv[201]	_	_
24-21	3865-3867	as	substance[201]	giv[201]	_	_
24-22	3868-3872	long	substance[201]	giv[201]	_	_
24-23	3873-3875	as	_	_	_	_
24-24	3876-3879	the	abstract[204]	giv[204]	_	_
24-25	3880-3888	pandemic	event|abstract[204]	giv|giv[204]	coref	25-23
24-26	3889-3893	H1N1	abstract|abstract[204]	giv|giv[204]	coref	25-25
24-27	3894-3899	virus	abstract[204]	giv[204]	_	_
24-28	3900-3902	is	_	_	_	_
24-29	3903-3914	circulating	_	_	_	_
24-30	3915-3918	and	_	_	_	_
24-31	3919-3926	causing	_	_	_	_
24-32	3927-3934	illness	abstract	giv	_	_
24-33	3935-3936	.	_	_	_	_

#Text=Since September 2009 , more than 75 Member States and territories have implemented immunization programmes , and 290 million doses of the pandemic ( H1N1 ) 2009 vaccine have been administered .
25-1	3937-3942	Since	_	_	_	_
25-2	3943-3952	September	time[206]	new[206]	_	_
25-3	3953-3957	2009	time[206]|time	new[206]|giv	appos	25-27
25-4	3958-3959	,	_	_	_	_
25-5	3960-3964	more	place[208]|place[209]	giv[208]|giv[209]	coref	25-5[209_208]
25-6	3965-3969	than	place[208]|place[209]	giv[208]|giv[209]	_	_
25-7	3970-3972	75	place[208]|place[209]	giv[208]|giv[209]	_	_
25-8	3973-3979	Member	place[208]|place[209]	giv[208]|giv[209]	_	_
25-9	3980-3986	States	place[208]|place[209]	giv[208]|giv[209]	_	_
25-10	3987-3990	and	place[209]	giv[209]	_	_
25-11	3991-4002	territories	place[209]|place	giv[209]|new	_	_
25-12	4003-4007	have	_	_	_	_
25-13	4008-4019	implemented	_	_	_	_
25-14	4020-4032	immunization	abstract|abstract[212]	new|new[212]	_	_
25-15	4033-4043	programmes	abstract[212]	new[212]	_	_
25-16	4044-4045	,	_	_	_	_
25-17	4046-4049	and	_	_	_	_
25-18	4050-4053	290	abstract[213]	new[213]	_	_
25-19	4054-4061	million	abstract[213]	new[213]	_	_
25-20	4062-4067	doses	abstract[213]	new[213]	_	_
25-21	4068-4070	of	abstract[213]	new[213]	_	_
25-22	4071-4074	the	abstract[213]|substance[217]	new[213]|giv[217]	_	_
25-23	4075-4083	pandemic	abstract[213]|event|substance[217]	new[213]|giv|giv[217]	_	_
25-24	4084-4085	(	abstract[213]|substance[217]	new[213]|giv[217]	_	_
25-25	4086-4090	H1N1	abstract[213]|abstract|substance[217]	new[213]|giv|giv[217]	_	_
25-26	4091-4092	)	abstract[213]|substance[217]	new[213]|giv[217]	_	_
25-27	4093-4097	2009	abstract[213]|time|substance[217]	new[213]|giv|giv[217]	_	_
25-28	4098-4105	vaccine	abstract[213]|substance[217]	new[213]|giv[217]	_	_
25-29	4106-4110	have	_	_	_	_
25-30	4111-4115	been	_	_	_	_
25-31	4116-4128	administered	_	_	_	_
25-32	4129-4130	.	_	_	_	_
